[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653248":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":30,"overallOfficials":11,"centralContacts":11,"locations":36,"responsibleParty":58,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":11,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":34,"conditions":78,"keywords":11,"overallStatus":80,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Patient reported outcome for gastroparesis symptoms as assessed by Gastroparesis Cardinal Symptom Index (GCSI) Questionnaire",null,"At Baseline and 3 Month Follow Up",{"measure":14,"description":11,"timeFrame":12},"Patient-Reported Severity and Frequency of Gastrointestinal Symptoms as Assessed by Gastrointestinal Symptom Rating Scale (GSRS) Questionnaire",{"measure":16,"description":11,"timeFrame":12},"Patient-Reported frequency, duration, and diagnostic criteria for conditions affecting the gastrointestinal tract for colonic motility and function as Assessed by Rome IV Diagnostic Questionnaire",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":22,"maskingDescription":11,"whoMasked":11},"NONE",[24],{"label":25,"type":26,"description":27,"interventionNames":28},"Participants initiating GLP-1RA therapy","EXPERIMENTAL","Participants starting the GLP-1RA or dual agonist therapy and taking their GLP-1RA or dual agonist therapy for 3 months.",[29],"Procedure: Gut motility quantification using a capsule after initiating GLP-1RA therapy",[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"PROCEDURE","Gut motility quantification using a capsule after initiating GLP-1RA therapy","Participants will undergo evaluation with the Atmo capsule at two time points: at baseline before starting the GLP-1RA or dual agonist therapy and after the subject has been taking their GLP-1RA or dual agonist therapy for 3 months. The total expected time for patient participation is up to 4 months from the time they start their GLP-1RA or dual agonist therapy.",[25],[37],{"facility":38,"status":11,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Cleveland Clinic","Cleveland","Ohio","44195","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-81.69541,41.4995,{"lat":48,"lon":47},[51,56],{"name":52,"role":53,"phone":54,"phoneExt":11,"email":55},"Samita Garg, MD","CONTACT","216-444-2384","GARGS@ccf.org",{"name":52,"role":57,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Samita Garg","Associate Professor of Medicine",[62],{"name":63,"class":64},"Atmo Biosciences Pty Ltd","INDUSTRY","100653248","whole-gut-motility-abnormalities-following-glp-1-receptor-agonist-glp-1ra-initiation-100653248",false,"NCT07784127","Whole Gut Motility Abnormalities Following GLP-1 Receptor Agonist (GLP-1RA) Initiation","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Initiating GLP-1RA or GLP-1RA\u002FGIP (dual agonist) therapy, or off GLP-1RA or GLP1-RA\u002FGIP therapy for greater than 3 months for the treatment of type 2 diabetes with or without obesity (BMI \\> 30 kg\u002Fm2) at the time of the baseline visit\n* Stable glucose control (HbA1c ≤ 9%) within 6 months of the baseline visit\n* Normal TSH within 6 months of baseline visit\n\nExclusion Criteria:\n\n* Current use of opiates, marijuana, anticholinergics, or pro-motility medications. Can be included if there is no utilization for at least 1 month.\n* Use of antibiotics within the past 2 weeks\n* History of gastric or bowel surgery\n* Known or suspected history or active intestinal obstruction or stricture\n* Pregnancy\n* Patients for whom English is not their primary language will be excluded.\n* Cognitively impaired persons or other vulnerable populations who are unable to provide informed consent will be excluded.","ALL","18 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[18],[79],"Diabetes","NOT_YET_RECRUITING","2026-08-20",{"date":83,"type":84},"2026-08-25","ACTUAL",{"date":86,"type":75},"2026-12",{"date":88,"type":75},"2028-12",{"name":5,"class":6},1]